Takeda To Add Mid-Stage Autoimmune Disease Candidate For $4B

  • Takeda Pharmaceutical Co Ltd TAK will acquire NDI-034858 from Nimbus Therapeutics, an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor for multiple autoimmune diseases. 
  • It is in an ongoing Phase 2b study in active psoriatic arthritis, and Takeda plans to investigate it for inflammatory bowel disease (IBD) and other autoimmune diseases.
  • Nimbus recently disclosed topline results from a Phase 2b study evaluating NDI-034858 in patients with moderate-to-severe plaque psoriasis. 
  • Takeda intends to present results from this Phase 2b study early in 2023. NDI-034858 is anticipated to enter Phase 3 in psoriasis in 2023. 
  • "This program further expands Takeda's GI clinical programs and therapeutic focus," said Andy Plump, president of R&D at Takeda. 
  • Under the terms of the agreement, Takeda will pay Nimbus $4 billion upfront and two milestone payments of $1 billion each upon achieving annual net sales of $4 billion and $5 billion. 
  • The upfront payment will be primarily funded by cash on hand. The transaction is expected to be finalized before the end of FY2022. 
  • Takeda ended the 30 September quarter with cash of $5.5 billion.
  • Price Action: TAK shares are up 2.75% at $15.33 on the last check Tuesday.

Posted In: BiotechLarge CapNewsHealth CareContractsMoversTrading IdeasGeneralBriefs